Eli Lilly Reports 39% Revenue Growth Driven by GLP-1 Drugs Amid High Valuation
Eli Lilly (LLY) reported strong third-quarter results, with revenue reaching $24.4 billion, a 39% increase year-over-year. This growth was primarily driven by its leading GLP-1 products, Mounjaro and Zepbound, which generated a combined $16.1 billion in sales, accounting for approximately two-thirds of the company's total revenue. While management raised full-year revenue guidance to between $91 billion and $92 billion, they slightly lowered earnings-per-share (EPS) projections to a range of $35 to $36. Despite the robust top-line performance, the stock's recent surge to all-time highs near $1,400 has raised concerns regarding its valuation. Trading at approximately 45 times trailing earnings, analysts suggest much of the anticipated growth may already be priced in, leaving a limited margin of safety for new investors.
Tickers: $LLY
Topics: earnings report GLP-1 drugs guidance increase revenue growth
Read the full article at Motley Fool
Part of the story Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs (10 articles)